EU recommendation for Lilly’s soft tissue cancer drug

pharmafile | September 19, 2016 | News story | Sales and Marketing CHMP, EMA, Eli Lilly, Lartruvo, soft tissue sarcoma 

The Committee for Medicinal Products for Human Use (CHMP) has recommended Eli Lilly’s Lartruvo (olaratumab) for treatment of adults with the rare cancer, soft tissue sarcoma.

Olaratumab is a human IgG1 monoclonal antibody that is designed to disrupt the PDGF Receptor-α (platelet-derived growth factor receptor α) pathway on tumour cells and on cells in the tumour microenvironment.

The pharma firm’s drug is to be used in combination with doxorubicin for treatment of the illness for whom surgery or radiotherapy is not suitable, and who have not been previously treated with doxorubicin.  

The FDA also fast-tracked review of the treatment in May.

The recommendation is based on data from Phase II of the JGDG study which showed a median improvement of 11.8 months in survival time of patients treated with a combination of doxorubicin plus Lartruvo compared to doxorubicin alone. The decision is thought to strongly encourage a marketing authorisation in the coming weeks.

Matt Fellows

Related Content

Is the pharmaceutical sector prepared to face a titanium dioxide ban?

Dr Subhashis Chakraborty, head of Global Product Management, ACG Capsules In the wake of the …


Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease

Eli Lilly has announced positive results from the TRAILBLAZER-ALZ 2 phase 3 trial assessing donanemab’s …

Eli Lilly shares positive analysis from phase 3 trial for lebrikizumab for atopic dermatitis

Eli Lilly has announced new secondary analysis from its phase 3 clinical development programme for …

Latest content